To evaluate the safety and efficacy of intravitreal injection of bevacizumab before vitrectomy in advanced proliferative diabetic retinopathy.
Methods
A randomized clinical trial was performed on 40 eyes of 40 patients. Inclusion criteria were advanced proliferative diabetic retinopathy with fractional retinal detachment and HbA1c <7%. Patients were randomly assigned into 2 groups. Patients in one group had an intravitreal injection (1.25 mg) of bevacizumab 48 hours before 23-G pars plana vitrectomy surgery was performed, whereas the other group did not. Best-corrected visual acuity, intraocular pressure, and fundus photographs were taken prior to surgery 1 week and 3 and 6 months postoperatively.
Results
Effective vitrectomy time was 8.05 minutes in the bevacizumab group vs 16.8 minutes in the non-bevacizumab group. Statistically significant differences were observed in visual acuity at 1 week and 3 and 6 months follow-up between the 2 groups (p<0.05 for each visit). Also, there was less bleeding intraoperatively in the bevacizumab group. Mean final visual acuity in the bevacizumab group was 0.82 logMAR and 2.01 logMAR in the non-bevacizumab group.
Conclusions
Adjuvant intravitreal injection of bevacizumab prior to vitrectomy in diabetic retinopathy with fractional retinal detachment significantly eases the procedure, diminishing intraoperative complications, and leads to a better visual outcome.
FerraraN., HillanK.J., NovotnyW.Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun2005; 333: 328–35.
2.
GragoudasE.S., AdamisA.P., CunninghamE.T.Jr.VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group: pegaptanib for neovascular age-related macular degeneration. N Engl J Med2004; 351: 2805–16.
3.
RosenfeldP.J., RichR.M., LalwaniG.A.Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am2006; 19: 361–72.
4.
MichelsS., RosenfeldP.J., PuliafitoC.A.Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology2005; 112: 1035–47.
5.
RosenfeldP.J., FungA.E., PuliafitoC.A.Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging2005; 36: 336–9.
IshikawaK., HondaS., TsukaharaY., NegiA.Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye2009; 23: 108–11.
10.
ChenE., ParkC.H.Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina2006; 26: 699–700.
11.
SatterthwaiteF.W.An approximate distribution of estimates of variance components. Biom Bull1946; 2: 110–4.
12.
ElliottA., FlanaganD.Macular detachment following laser treatment for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol1990; 228: 438–41.
13.
Diabetic Retinopathy Vitrectomy Study.Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management: Diabetic Retinopathy Vitrectomy Study Report 1. Ophthalmology1985; 92: 492–502.
14.
The Diabetic Retinopathy Vitrectomy Study Research Group.Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study Report 2. Arch Ophthalmol1985; 103: 1644–52.
15.
The Diabetic Retinopathy Vitrectomy Study Research Group.Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 3. Ophthalmology1988; 95: 1307–20.
16.
The Diabetic Retinopathy Vitrectomy Study Research Group.Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: clinical application of results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 4. Ophthalmology1988; 95: 1321–34.
17.
Diabetic Retinopathy Vitrectomy Study Group.Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5 [erratum in 1990; 108: 1452]. Arch Ophthalmol1990; 108: 958–64.
18.
FaulbornJ., ConwayB.P., MachemerR.Surgical complications of pars plana vitreous surgery. Ophthalmology1978; 85: 116–25.
19.
CarterJ.B., MichelsR.G., GlaserB.M.Iatrogenic retinal breaks complicating pars plana vitrectomy. Ophthalmology1990; 97: 848–53.
20.
ChagnonA., PayanJ., LevyC., ChassainC.Intraocular pressure during vitrectomy in the diabetic patient. Bull Soc Ophtalmol Fr1989; 89: 171–8.
21.
ThompsonJ.T., GlaserB.M., MichelsR.G.The use of intravitreal thrombin to control hemorrhage during vitrectomy. Ophthalmology1986; 93: 279–82.
22.
O'GradyG.E.The use of intravitreal thrombin to control hemorrhage during vitrectomy. Ophthalmology1986; 93: 1367.
23.
ImamuraY., KameiM., MinamiM.Heparin-assisted removal of clotting preretinal hemorrhage during vitrectomy for proliferative diabetic retinopathy. Retina2005; 25: 793–5.
24.
SiamA.L.External diathermy treatment of proliferative diabetic retinopathy with vitreous haemorrhage. Br J Ophthalmol1986; 70: 118–21.
25.
YanyaliA., AytugB., HorozogluF., NohutcuA.F.Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol2007; 144: 124–6.
YehP.T., YangC.M., LinY.C., ChenM.S., YangC.H.Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina2009; 29: 768–74.
28.
JonasJ.B., SpandauU.H., RenschF., Von BaltzS., SchlichtenbredeF.Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther2007; 23: 240–2.
29.
ArevaloJ.F., MaiaM., FlynnH.Jr.Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol2008; 92: 213–6.
30.
ChungE.J., KohH.J.Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection. Korean J Ophthalmol2007; 21: 185–7.
31.
EmersonM.V., LauerA.K.Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. Bio Drugs2007; 21: 245–57.
32.
OshimaY., ShimaC., WakabayashiT.Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology2009; 116: 927–38.
